Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment RegistryFrank Stenner, Richard Cathomas, Rudolf Morant et al.|Clinical Genitourinary Cancer|2017Cited by 7
Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)Roger von Moos, Arnoud J. Templeton, Hanne Hawle et al.|Annals of Oncology|2018Cited by 4